PRODUCTS & INNOVATION
ABBOTT STATEMENT ON FIRST FAMILY COVID-19 DIAGNOSIS
Oct 2 2020
We wish the President and First Lady a speedy recovery. While we don’t know the details on who was tested and on which devices, we know that more than 11 million Americans have taken the ID NOW test, helping to stop the spread of the virus. We also know from our large post-authorization study that ID NOW demonstrates performance of 95% sensitivity and 98% specificity in people within 7 days post symptom onset.
Citing data from the flawed and debunked NYU study is careless and irresponsible. Science matters. The small NYU study on ID NOW was rife with limitations, including testing methods, poor sample collection, and the inclusion of many patients who were weeks after having reported symptoms.
Cardiovascular Tech: Surveillance for Your Health
Some Perspective on Testing
Please be aware that the website you have requested is intended for the residents of a particular country or region, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.
The website you have requested also may not be optimized for your specific screen size.
Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.
The website that you have requested also may not be optimized for your screen size.